- Home
- DYNX vs PROK Comparison
DYNX vs PROK Comparison
Compare DYNX & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYNX
- PROK
- Stock Information
- Founded
- DYNX 2024
- PROK 2015
- Country
- DYNX United States
- PROK United States
- Employees
- DYNX N/A
- PROK N/A
- Industry
- DYNX
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DYNX
- PROK Health Care
- Exchange
- DYNX NYSE
- PROK Nasdaq
- Market Cap
- DYNX 219.0M
- PROK 237.4M
- IPO Year
- DYNX 2024
- PROK N/A
- Fundamental
- Price
- DYNX $9.80
- PROK $1.53
- Analyst Decision
- DYNX
- PROK Buy
- Analyst Count
- DYNX 0
- PROK 5
- Target Price
- DYNX N/A
- PROK $4.50
- AVG Volume (30 Days)
- DYNX 115.2K
- PROK 500.4K
- Earning Date
- DYNX 01-01-0001
- PROK 11-12-2024
- Dividend Yield
- DYNX N/A
- PROK N/A
- EPS Growth
- DYNX N/A
- PROK N/A
- EPS
- DYNX N/A
- PROK N/A
- Revenue
- DYNX $2,124,981.00
- PROK N/A
- Revenue This Year
- DYNX N/A
- PROK N/A
- Revenue Next Year
- DYNX N/A
- PROK N/A
- P/E Ratio
- DYNX N/A
- PROK N/A
- Revenue Growth
- DYNX N/A
- PROK N/A
- 52 Week Low
- DYNX $9.91
- PROK $1.18
- 52 Week High
- DYNX $9.98
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- DYNX N/A
- PROK 36.04
- Support Level
- DYNX N/A
- PROK $1.70
- Resistance Level
- DYNX N/A
- PROK $2.03
- Average True Range (ATR)
- DYNX 0.00
- PROK 0.19
- MACD
- DYNX 0.00
- PROK -0.06
- Stochastic Oscillator
- DYNX 0.00
- PROK 8.33
About DYNX DYNAMIX CORP
Dynamix Corp is a blank check company.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.